［精华］TCT2007 DAILY NEWS (TCT2007每日新闻荟萃)
发布于:2007-10-24 15:50
医心网作为CRF独家授权网站，第一时间向您精彩呈现TCT 2007 DAILY NEWS!
一、中文版
1. SPIRIT III试验1年结果公布：Xience V支架与TAXUS支架没有差别
2. DES有效性超过预期
6. 永远缅怀介入心脏病学先驱Andreas Gruentzig
10.美国心脏病学院动员医生行动起来减少就诊-介入时间(Door to Ballon)
11. 经皮腔内动脉成型术（PTA）联合支架置入治疗股浅动脉疾病优于单纯PTA
12. TRIAS HR Pilot试验：Genous内皮祖细胞捕获支架的可行性研究
13. Barry T Katzen获得2007年TCT 终身成就奖
15. MIDAS研究显示DES 显著降低急性心肌梗死的全因死亡和心血管死亡率
17. 心脏病学家对军人职业的讨论
18. TAXUS系列研究的数据显示Thienopyridines治疗超过一年没有明显效果
19. 药物洗脱支架内血栓形成的病理机制、发生率以及危险因素
20. Biolimus A9 药物洗脱支架并不逊于Taxus Liberte支架
22. 糖尿病患者置入DES血栓发生率更高，但全因死亡率没有增加
23. ENDEAVOR IV 试验结果公布: ENDEAVOR支架与TAXUS支架主要终点TVF没有差别
26. PROSPECT试验－基线资料显示VH IVUS可识别高危病变
27. DES益处大于血栓形成的危险
28. DESERT 注册试验：DES血栓形成的预测因素分析
30. SEACOAST试验:经冠脉注射干细胞6个月安全性研究
31. Schatz医生回忆早期介入治疗历程－－介入治疗30年历程
32. 脂肪干细胞：临床前研究展现其在心脏领域良好的应用前景
35. 血管内超声识别易损斑块进展—对比剂可更好地分析血管壁及斑块
二、英文版
SPIRIT III at 1 Year: Xience V Noninferior to Taxus
Tribute Paid to Andreas Gruentzig
Biolimus A9-eluting Stent Noninferior to Taxus Liberte
Biodegradable Polymer-based, Polymer-free, Cypher Comparable
TRIAS HR Pilot Trial: Genous EPC-capturing Stent Feasible
Transfemoral Aortic Valve Replacement Effective in High-risk Patients
Next-generation DES Targeting More Complex Lesions
Pathology, Prevalence, and Risk Factors of Stent Thrombosis After DES
Nationwide Initiatives Reducing Door-to-Balloon Times
When Schatz met Palmaz and invented the coronary stent
Coronary Angioplasty: A Timeline
Expanding Angioplasty to Complex Lesions
OAT: No Clinical Relevance for CTO Recanalization
GM-CSF and Peripheral Stem Cell Infusion Improved Endothelial Healing
Adipose stem cells show promise in preclinical cardiac work
SEACOAST: Direct Coronary Delivery of Stem Cells Safe at Six Months
IVUS Guidance Needed for DES Left Main Procedures
New Programs Help Reduce Door-to-Balloon Time
Fewer Adverse Events With In-lab Abciximab for PCI
MYOHEART: Myoblast Transplantation Shows Promise in CHF Patients
Supersaturated O2Reduced Infarct Size in High-risk Patients
Barry T. Katzen Presented with 2007TCT Career Achievement Award
MIDAS: DES Significantly Reduced All-Cause and Cardiovascular Mortality
Witnessing the First PCTA 30 Years Ago
Drug-eluting Stents Associated With Positive Outcomes Over Time
No Benefit of Thienopyridines Beyond 1 Year in Analysis of TAXUS Data
Swedish Registry: No Increased MortalityWith Drug-eluting Stents
DES Efficacy Expands Beyond Current Labeling
Do Drug-eluting Stents Decrease Mortality?
PTA and Stent Better Than PTA in Superficial Femoral Artery Disease
Cardiologist Discusses Army Career
来源： 医心网
评论列表：（评论 10 ）以下网友评论只代表网友个人观点，不代表本站观点。 
最短5个字
医心微信 >
京公网安备 11010102002968号